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SUMMARY
An inducible gene expression program is a hallmark
of the host inflammatory response. Recently, long
intergenic non-coding RNAs (lincRNAs) have been
shown to regulate themagnitude, duration, and reso-
lution of these responses. Among these is lincRNA-
Cox2, a dynamically regulated gene that broadly con-
trols immune gene expression. To evaluate the in vivo
functions of this lincRNA, we characterized multiple
models of lincRNA-Cox2-deficient mice. LincRNA-
Cox2-deficient macrophages and murine tissues
had altered expression of inflammatory genes. Tran-
scriptomic studies from various tissues revealed that
deletion of the lincRNA-Cox2 locus also strongly
impaired the basal and inducible expression of the
neighboring gene prostaglandin-endoperoxide syn-
thase (Ptgs2), encoding cyclooxygenase-2, a key
enzyme in the prostaglandin biosynthesis pathway.
By utilizing different genetic manipulations in vitro
and in vivo, we found that lincRNA-Cox2 functions
through an enhancer RNA mechanism to regulate
Ptgs2. More importantly, lincRNA-Cox2 also func-
tions in trans, independently of Ptgs2, to regulate crit-
ical innate immune genes in vivo.
INTRODUCTION
Activation of myeloid cells is associated with differential expres-
sion of immune genes involved in host defense, tissue repair, and
resolution of inflammation. Toll-like receptors (Tlrs) are germline-
encoded receptors critical for the activation of signaling path-
ways controlling immune response genes. Dysregulation of
these pathways can lead to deleterious autoinflammatory condi-
tions, which can contribute to autoimmunity or cancer (Gajewski
et al., 2013; Gierut et al., 2010; Masters et al., 2009). Tight
control of these inflammatory signaling cascades is required to
prevent host damage and is achieved both transcriptionally
and posttranscriptionally.
The majority of mammalian genomes are pervasively tran-
scribed, producing thousands of noncoding RNAs (ENCODE
Project Consortium, 2012). Interestingly, the expression of these
noncoding genes is highly cell type-specific (Morris and Mattick,
2014), and their function remains largely unknown. Long inter-
genic noncodingRNAs (lincRNAs) are a subclass of longnoncod-
ing RNAs (lncRNAs) that form the largest class of RNA produced
in the genome. The tremendous number of newly annotated
lincRNAs and their low evolutionary conservation has led to de-
bates about their functionality (Bassett et al., 2014). However,
the number of characterized lincRNAs is growing, and this class
of gene has been shown to control various biological processes,
including somatic tissuedifferentiation (Kretz et al., 2013), X chro-
mosome inactivation (Carmona et al., 2018; Engreitz et al., 2013;
Je´guet al., 2017), andorgandevelopment (Andersonet al., 2016).
LincRNAs function to control gene expression either in cis,
where they influence the expression and/or chromatin state of
neighboring genes, or in trans, where the lincRNA leaves the
site of transcription and affects genes on different chromosomes
(Kopp and Mendell, 2018; Liang et al., 2018; Neumann
et al., 2018). These trans-acting lincRNAs, such as FOXF1
adjacent non-coding developmental regulatory RNA (FENDRR),
long-intergenic non-coding-erythroid prosurvival (linc-EPS), and
Nettoie Salmonella pas Theiler’s (NeST), can function to regulate
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chromatin states (Atianand et al., 2016; Gomez et al., 2013;
Grote et al., 2013; Sauvageau et al., 2013), influence nuclear
structure and organization (Rinn and Guttman, 2014), or interact
with and regulate the behavior of proteins and/or other RNA
molecules (Covarrubias et al., 2017; Kawasaki et al., 2018; Lee
et al., 2016; Wang et al., 2017).
lincRNAs have recently been shown to regulate the develop-
ment and function of immune cells (Kotzin et al., 2016; Wang
et al., 2014, 2017). Previous work from our lab and others
defined an immune-inducible lincRNA, lincRNA-Cox2 (synonym
Ptgs2os2) with broad trans-regulatory activity on inflammatory
responses (Carpenter et al., 2013; Covarrubias et al., 2017; Hu
et al., 2016; Tong et al., 2016; Xue et al., 2018). In macrophages,
where this lincRNA was highly induced upon inflammatory
activation, lincRNA-Cox2 functioned to activate and repress
distinct classes of innate immune genes (Carpenter et al.,
2013). However, like most lincRNAs and protein-coding genes,
the cis- and trans-regulatory elements encoded within the locus
remain unstudied in vivo. Most recently, some lincRNAs have
been discovered to have the ability to function both in cis and
in trans (Carmona et al., 2018; Li et al., 2012; Yin et al., 2015).
Here we created a combination of different genetic deletion
models to study the role of the lincRNA-Cox2 locus in macro-
phages and in murine models in vivo. Consistent with prior
work, we found that lincRNA-Cox2-deficient macrophages had
altered expression of numerous inflammatory genes (Carpenter
et al., 2013; Covarrubias et al., 2017). In addition, we observed
a profound cis function for lincRNA-Cox2: lincRNA-Cox2-defi-
cient mice had severely reduced expression of the neighboring
gene Ptgs2, a gene that encodes for cyclooxygenase-2 (Cox2),
a central enzyme of the prostaglandin biosynthesis pathway,
across several tissues. This finding provides evidence for
a previously unrecognized cis function for lincRNA-Cox2. We
have data that support lincRNA-Cox2 functioning through an
RNA-mediated mechanism as an enhancer RNA (eRNA) to
regulate Ptgs2 expression. Crossing our lincRNA-Cox2-deficient
mice to wild-derived mice (MOLF) that have a distinct genetic
background provides critical evidence that lincRNA-Cox2
indeed functions on the same chromosome to regulate Ptgs2
expression levels.
Finally, to distinguish the cis-regulatory element from the trans
activity of the RNA transcript, we generated a ‘‘mutant’’ mouse
model that retained the exonic sequences of the lincRNA but
lacked the intron and splicing capabilities. This resulted in a
mouse with a low basal expression level of lincRNA-Cox2, but
the transcript is no longer inducible following inflammatory stim-
ulation. In the mutant mouse, Ptgs2 expression is comparable
with wild-type mice as the eRNA activity of the lincRNA-Cox2
locus ismaintained. Using a conventional in vivo lipopolysaccha-
ride (LPS) shock model, we identify an additional role for the
lincRNA-Cox2 transcript in the trans regulation of a subset of
immune genes as well as an organ-specific role independent
of Ptgs2 biology. Collectively, these observations reveal a
bimodal action of gene regulation by the lincRNA-Cox2
transcript: a trans-regulatory function controlling immune genes
such as cytokines globally and a separate enhancer function
acting to regulate prostaglandin biosynthesis via Ptgs2 (Cox2).
Thus, lincRNA-Cox2 represents a regulator of the Ptgs2 pathway
as well as an important mediator of immunity beyond the prosta-
glandin pathway.
RESULTS
Genetic Deletion of lincRNA-Cox2 Alters Immune Gene
Expression in Macrophages
LincRNA-Cox2 is encoded on chromosome 1 and transcribed
from the negative strand. The mature sequence has 2 exons
and is 1.7 kb long. Its nearest protein coding gene, prosta-
glandin-endoperoxide synthase 2 (Ptgs2 or Cox2), is 50 kb
upstream and transcribed on the positive strand (Figure 1A).
A lincRNA-Cox2 knockout (KO) mouse was generated by
removing the entire genomic locus (5.9 kB), except for the pro-
moter, and replacing it with a LacZ reporter cassette (Sauvageau
et al., 2013; Figure 1B). KO mice were born at expected Mende-
lian frequencies with no obvious developmental abnormalities
(Sauvageau et al., 2013). We and others have previously
published that lincRNA-Cox2 acts to positively and negatively
regulate the expression of distinct classes of innate immune
genes (Carpenter et al., 2013; Covarrubias et al., 2017; Hu
et al., 2016; Tong et al., 2016; Xue et al., 2018). In those studies,
short hairpin RNA (shRNA)-based knockdown of lincRNA-
Cox2 reduced the levels of pro-inflammatory cytokines like
Interleukin-6 (Il6) in bone-marrow derived macrophages
(BMDMs) activated with LPS, whereas a number of interferon-
stimulated genes (ISGs) were expressed at higher levels. Here,
using genetic approaches, we find that lincRNA-Cox2-deficient
BMDMs (Figure 1C) produced less Il6 (Figure 1D) and more
Chi3L as well as IfI202b, an ISG, following LPS (Tlr4) and R848
(Tlr7) stimulation (Figures 1E and 1F).
Ptgs2 Levels Are Reduced in lincRNA-Cox2 KO Mice
The lincRNA-Cox2 KO mouse was generated so that the locus
remains transcriptionally active and LacZ staining can be used
as a surrogate for lincRNA-Cox2 expression (Sauvageau et al.,
2013). Staining of several organs from these mice revealed the
in vivo expression of lincRNA-Cox2 in both the brain (dorsal
cerebral cortex) and the lung under steady-state conditions
(Figure 2A). Further, RNA sequencing (RNA-seq) from a variety
of organs confirmed that lincRNA-Cox2 was most highly ex-
pressed in the lung at steady state (Figure S1A). To identify
the target genes of lincRNA-Cox2 at steady state, we performed
RNA-seq on whole lung tissue, comparing wild-type and
lincRNA-Cox2-deficient mice. Using differential expression
sequencing 2 (DESeq2) with a cut off of 2.5-fold and a p value
of 0.05, 476 genes showed altered expression (273 were
upregulated and 203 were downregulated) (Table S1). Among
the most significantly downregulated genes was Ptgs2 (Fig-
ure 2B, highlighted in red).
Next we wanted to investigate the lincRNA-Cox2 locus at
higher resolution and across different tissues to understand
whether this effect was specific to Ptgs2 or whether the genetic
manipulation of the locus altered other neighboring genes. To
that end, we compared the transcriptomes from WT and KO
animal brains and lungs and generated cis region plots spanning
a 1-Mb window in the vicinity of the lincRNA-Cox2 locus. In both
the lung and brain, which have high expression of lincRNA-Cox2
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represented by LacZ staining in organs fromKOmice (Figure 2A),
the only gene affected in this region at steady state was Ptgs2
(Figures S2A and S2B). To determine whether the cis effect on
Ptgs2 persisted after an inflammatory stimulus in vivo, a context
in which the lincRNA transcript is highly induced, we measured
the expression of Ptgs2 in the lung, spleen, and liver following
intraperitoneal (i.p.) injection of E. coli LPS (20 mg/kg) for 6 hr.
In WT mice, lincRNA-Cox2 and Ptgs2 were inducible in the
spleen and liver (Figures 2C–2G) following LPS treatment.
Ptgs2 levels were reduced in all tissues examined from
lincRNA-Cox2 KO mice following LPS challenge (Figures
2D–2H). LacZ expression remained comparable with lincRNA-
Cox2 expression in the tissues fromKOmice following LPS treat-
ment, confirming that the locus is actively transcribed (Figures
S2C and S2D).
We also examined Ptgs2 levels in BMDMs from the lincRNA-
Cox2 KO mice following stimulation with various Tlr ligands.
In each case, the inducible transcriptional expression of Ptgs2
was greatly reduced (Figure 2I). We confirmed this effect at the
protein level in lincRNA-Cox2-deficient BMDMs by immunoblot-
ting for Ptgs2 (Figure 2J). Ptgs2 is the central enzyme of the pros-
taglandin pathway catalyzing the conversion of arachidonic acid
to prostaglandins (Ricciotti and FitzGerald, 2011). Consistent
with the reduced expression of Ptgs2 RNA and protein, there
was reduced pro-inflammatory prostaglandin E2 (PGE2) produc-
tion in lincRNA-Cox2-deficient cells as measured by mass spec-
trometry (Figure 2K). Together, all of these data indicate that the
lincRNA-Cox2 locus controls the expression of Ptgs2 and, there-
fore, prostaglandin biosynthesis.
Rescue of Mature lincRNA-Cox2 Fails to Restore
Inducible Ptgs2 Expression in Macrophages
LincRNA-Cox2 and Ptgs2 show parallel inducible expression
kinetics following Tlr activation. In prior work, we showed that
knocking down the lincRNA transcript using shRNAhad no effect
on the expression of Ptgs2 (Carpenter et al., 2013). This observa-
tion contrasts with the strong cis effect of the lincRNA locus
observed in our KO model and could be consistent with a
DNA-mediated enhancer effect, a mechanism that has previ-
ously been reported for other lincRNA loci (Engreitz et al.,
2016; Groff et al., 2016; Joung et al., 2017; Paralkar et al.,
2016). To gain more insight into the molecular basis for this cis
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(A) Schematic showing that the lincRNA-Cox2 locus is 50 kb away from its closest protein-coding gene, Ptgs2.
(B) Schematic depicting the generation of the lincRNA-Cox2 knockout mouse in which the locus has been replaced with a LacZ reporter construct.
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effect, we reconstituted lincRNA-Cox2-deficient primary
BMDMs with the full-length spliced mature RNA transcript (Fig-
ure 3A) via plasmid electroporation. Despite restoration of
lincRNA-Cox2 to a level of expression comparable with that
seen in wild-type (WT) cells, Ptgs2 expression could not be
rescued (Figure 3B). To control for possible effects mediated
by knockin of the LacZ transgene, we also generated a BMDM
line lacking lincRNA-Cox2 using CRISPR/Cas9 to validate these
findings. We designed guide RNAs to the 50 and 30 ends of the
lincRNA-Cox2 gene as outlined in Figure 3C, using two guide
RNAs that remove the entire locus encoding the gene (while
leaving the promoter intact). KO of lincRNA-Cox2was confirmed
by qRT-PCR (Figure 3D). Ptgs2 levels were also impaired in
these Cas9-edited cells (Figure 3E). Again, reconstitution
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with the full-length lincRNA-Cox2 transcript by lentiviral expres-
sion, which localized to both the nuclear and cytoplasmic
compartments (Figures S3A and S3B), failed to rescue this
phenotype (Figures 3F and 3G).
lincRNA-Cox2 Functions through an eRNA Mechanism
to Regulate Ptgs2
Recently, it has been shown that non-coding RNA loci have the
potential to harbor enhancer activities (Engreitz et al., 2016; Groff
et al., 2016; Kim et al., 2015; Kotzin et al., 2016; Melo et al., 2013;
Paralkar et al., 2016; Ørom et al., 2010). Because the effect of
lincRNA-Cox2 deficiency on Ptgs2 levels was not rescued by
ectopic expression, we speculated that the lincRNA-Cox2 locus
harbored a DNA enhancer element controlling Ptgs2 expression.
LincRNA-Cox2 possesses two exons, with the majority of the
sequence lying within exon 2. Using CRISPR/Cas9, we excised
exon 2 from lincRNA-Cox2 in BMDMs (Figure 3H) and confirmed
this deletion by qRT-PCR (Figure 3K). Ptgs2 was measured by
qRT-PCR, and expression was markedly reduced in the exon 2
KO BMDMs, again suggesting that either the lincRNA transcript
or a DNA enhancer element within exon 2 is required for the ac-
tivity on Ptgs2 (Figure 3L). These data confirm that there is no
enhancer activity lying within exon 1, which remains intact in
this model. To determine whether there are any enhancer marks
present within exon 2 of lincRNA-Cox2, we studied chromatin
immunoprecipitation sequencing (ChIP-seq) of histone marks
associated with enhancers, including histone 3 lysine 4 (H3K4)
mono-methylation, as well as p300 binding from the Mouse
Encode project and from Lara-Astiaso et al. (2014) and Stama-
toyannopoulos et al. (2012). We were surprised that there was
no evidence of any enhancer within exon 2 of lincRNA-Cox2
and, instead, enhancer marks were identified upstream of the
transcription start site of lincRNA-Cox2 (Figure 3I; Figure S4).
These data suggest that this locus might function instead
as an eRNA in which transcription of lincRNA-Cox2 functions
to connect the enhancer region with the Ptgs2 locus to drive
expression of the protein. The enhancer region within the
lincRNA-Cox2 promoter remains intact in the KO mouse, and
the locus is transcriptionally active, but there is a strong defect
in Ptgs2 levels. Only the lincRNA-Cox2 transcript is absent in
this model, and because there are no identifiable enhancer ele-
ments within this region, it suggests that specific transcription
of the lincRNA-Cox2 sequence is driving this phenotype as an
eRNA.
To test whether lincRNA-Cox2 can function as an eRNA, we
used CRISPR interference (CRISPRi) as outlined in Figure 3J to
inhibit transcription of the locus. We successfully knocked
down lincRNA-Cox2 by over 95% using two independent guide
RNAs in a clonal cell line (Figure 3M), and each led to amore than
95% decrease in Ptgs2 expression, as assayed using qRT-PCR
(Figure 3N). This result was replicated in a second CRISPRi
BMDM cell line (Figures S5C and S5D). These data strongly indi-
cate that it is locus-specific transcription of lincRNA-Cox2 and
not a DNA element within the exonic sequence of the gene that
is critical to its function to control Ptgs2 levels.
To determine whether lincRNA-Cox2 regulates Ptgs2 on the
same chromosome, one final experiment was performed using
mice with distinct genetic backgrounds. We took advantage of
thewild-derivedmouse strainMOLF, which is genetically distinct
from the common laboratory C57/Bl6 mice. MOLFmice possess
numerous SNPs that are distinct compared with C57/Bl6 mice
(Doran et al., 2016). Within the last exon of Ptgs2, MOLF mice
have 5 distinct SNPs that can be used to distinguish the C57/
Bl6 and MOLF alleles. As outlined in Figure 4A, we crossed WT
C57/Bl6 or lincRNA-Cox2 KO C57/Bl6 mice with MOLF-WT
mice to determine how loss of lincRNA-Cox2 affects Ptgs2. By
qRT-PCR, we show that lincRNA-Cox2 expression is lost in the
KO mice, whereas the native promoter is intact, represented
by LacZ expression (Figures 4B and 4C). When examining the
heterozygousmice, theMOLF-KOmice had reduced expression
of lincRNA-Cox2 and Ptgs2 compared withMOLF-WTmice (Fig-
ures 4B and 4D). Using RNA-seq, we determined that only the
lincRNA-Cox2 KO allele (C57/Bl6) had decreased expression
of Ptgs2. The MOLF-WT allele, which has an intact lincRNA-
Cox2 gene, was unaffected by the loss of lincRNA-Cox2 (Figures
4E and 4F). These results support the finding that lincRNA-Cox2
functions to regulate the expression of Ptgs2 on the same chro-
mosome and is graphically summarized in Figure 4G.
Ptgs2 Expression Is Not Required for Transcriptional
Activity of lincRNA-Cox2
Because lincRNA-Cox2 and Ptgs2 show parallel expression
kinetics following an inflammatory stimulus (Carpenter et al.,
2013), we wanted to explore whether the regulatory interaction
between lincRNA-Cox2 and Ptgs2was unidirectional or whether
Ptgs2 itself affects the expression levels of the lincRNA. In addi-
tion, we wanted to understand whether the effect on Ptgs2 was
responsible for the changes in inflammatory genes, such as Il6.
To address this question, we crossed conditional Ptgs2 flox/
flox mice (Wang et al., 2009) to Vavi-Cre mice to delete Ptgs2
in all hematopoietic cells. We generated BMDMs from these
Ptgs2f/f-Vavi-Cre mice and confirmed deficiency of Ptgs2 by
(F and G) Cas9 KO cells were reconstituted using a lentiviral vector expressing full-length lincRNA-Cox2. LincRNA-Cox2 (F) and Ptgs2 (G) levels were measured
by qRT-PCR.
(H) A schematic outlining the strategy to knock down lincRNA-Cox2 expression using CRISPRi.
(I) University of California, Santa Cruz (UCSC) browser tracks indicating histone marks, H3K4me1 (enhancer), H3K4me3 (active transcript), and p300 peaks
measured using ChIP in BMDMs and lungs are outlined.
(J) Schematic outlining the strategy to remove exon 2 of lincRNA-Cox2 using CRISPR/Cas9.
(K and L) Control (Ctl) and exon 2 KO BMDMs were stimulated with LPS for 6 hr, and expression levels of lincRNA-Cox2 (K) and Ptgs2 (L) were measured by
qRT-PCR.
(M and N) lincRNA-Cox2 (M) and Ptgs2 (N) levels were measured in 6-hr LPS-stimulated BMDMs following knockdown of lincRNA-Cox2 using CRISPRi. Data
represent 3 combined biological replicates representative of 3 individual experiments.
Error bars represent standard deviation of biological triplicates. Student’s t tests were performed usingGraphPad Prism. Asterisks indicate statistically significant
differences between mouse lines (*pR 0.05, **pR 0.01, ***pR 0.005).
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immunoblotting and qRT-PCR in BMDMs stimulated with LPS
(Figures 5A and 5B). The induction of lincRNA-Cox2 proceeded
normally in Ptgs2-deficient BMDMs (Figure 5C). Importantly, the
induction of Il6 and Ifi202b, which were both affected by
lincRNA-Cox2 deficiency, was normal in Ptgs2-deficient cells
(Figures 5D and 5E). Together, these results suggest that the
lincRNA-Cox2 transcript can regulate genes in trans that are
not normally regulated byPtgs2. Thus, lincRNA-Cox2may repre-
sent an important modulator within and outside of the Ptgs2
pathway.
Additionally, we used the BMDM CRISPRi clonal cell lines to
target Ptgs2 using two independent guide RNAs, as represented
in Figure 5F. CRISPRi-mediated knockdown of Ptgs2 by more
than 90% had no effect on the transcription of lincRNA-Cox2
upon LPS stimulation. These data further confirm that Ptgs2,
RNA or protein, is not necessary for transcriptional activity of
lincRNA-Cox2 basally or after inflammatory stimulation (Figures
5G and 5H; Figures S6C and S6D), whereas lincRNA-Cox2 is
required for Ptgs2 expression.
A lincRNA-Cox2 Splicing Mutant Mouse Fails to Produce
Any Inducible lincRNA-Cox2 Transcript
To determine the trans functions of this lincRNA transcript
independent of its role in regulating Ptgs2, we generated a
mousemodel with a deletion of the2.3-kb intronic region utiliz-
ing CRISPR/Cas9 (hereafter referred to as mutant mice). We
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designed two guide RNAs targeting the 50 and 30 splice sites of
lincRNA-Cox2. Exon 2 remained completely intact, whereas
50 bp were deleted from exon 1 (Figure 6A). PCR genotyping
confirmed the mutant as described in Figure 6B. These mice
were also born at expected Mendelian frequencies with no
obvious developmental abnormities. We generated BMDMs
from the mutant mice and examined the expression of lincRNA-
Cox2 in response to LPS challenge. Although the lincRNA-Cox2
transcript was inducible following LPS stimulation in WT BMDM
cells, there was only very low basal expression of lincRNA-
Cox2 in the mutant BMDM cells, as measured by qRT-PCR
(Figure 6C).
In contrast to data we obtained with the full gene KO, Ptgs2
levels were comparable between the WT and mutant BMDMs
(Figure 6D). We next examined Ptgs2 levels in tissues, specif-
ically the lung, where lincRNA-Cox2 is most highly expressed,
and the spleen, where the majority of white blood cells are
stored (Figures 2A, 2C, and 2E, Figure S1A). In the mutant,
intron-less mouse, lincRNA-Cox2 levels were dramatically
reduced in the lung and spleen following LPS stimulation (Fig-
ures 6E and 6G). Again, there was no effect on Ptgs2 levels
within the lung and spleen of mutant mice (Figures 6F and
6H). These observations support the hypothesis that this locus
can function as an enhancer to regulate Ptgs2 and that this
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eRNA activity is maintained in this model. The enhancer
located prior to the start site of the locus in conjunction with
the basal transcript work together to mediate these effects
on Ptgs2.
lincRNA-Cox2 Regulates Distinct Sets of Genes in the
Lung and Spleen
Now having two separate mouse models, a complete deletion
KOmouse, and an intron-less mutant mouse, we asked whether
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Figure 6. A Lung-Specific Role for lincRNA-Cox2 Acting in trans
(A) Schematic outlining the strategy to remove the intron of lincRNA-Cox2 using CRISPR/Cas9 to generate mutant mice.
(B) Genotyping data confirming the mutation within the lincRNA-Cox2 locus.
(C and D) BMDMswere isolated fromWT andmutantmice and stimulatedwith LPS orMock (water), and lincRNA-Cox2 (C) andPtgs2 (D) levels weremeasured by
qRT-PCR. Error bars represent standard deviation of biological triplicates.
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were measured by qRT-PCR.
(I) Experimental schematic outlining the sequencing strategy of in vivo experiment comparing WT, KO, and mutant mice.
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the absence of the lincRNA-Cox2 transcript has a trans and
organ-specific role in vivo. lincRNA-Cox2 is expressed at high
levels in the lung and very low in the spleen (Figures 2D and
2E; Figure S1A). The expression of lincRNA-Cox2 is inducible
upon LPS challenge in the spleen and slightly reduced in the
lung (Figures 2D and 2E). To define the global regulatory role of
lincRNA-Cox2, we challenged WT, KO, and mutant mice by i.p.
injection of E. coli LPS for 6 hr, followed by RNA-seq of the
spleen and lung, as represented in Figure 6I.
DESeq2 analysis was used to determine the differentially ex-
pressed (DE) genes between WT versus KO, WT versus mutant,
or KO versus mutant in both the lung and spleen (Figure 6J). The
KO versus WT mice had 312 DE genes in the lung and 313 DE
genes in the spleen (Figure 6J). The mutant versus WT mice
had 115 DE genes in the lung and 179 DE genes in the spleen
(Figure 6J). When comparing gene expression of mutant mice
with KOmice, there were hundreds of significantly DE genes, re-
inforcing that these mice had very distinct phenotypes from one
another because of the cis and trans functions of lincRNA-Cox2
(Figures 6J–6L). Interestingly, when comparing mutant lincRNA-
Cox2-specific DE genes, there are only six that overlap between
the spleen and lung (Figure 6M). Of these six genes, only one
gene changed from being upregulated to downregulated from
the spleen to the lung,Ptprh (synonymSap-1) (Figure S7C; Bujko
et al., 2017). Database for Annotation, Visualization, and Inte-
grated Discovery (DAVID) analysis of the differentially expressed
genes of the spleen and lung show similar pathways, such as
glycoprotein and inflammatory response, as well distinct path-
ways, such as fibronectin and heparin binding in the spleen or
cellular homeostasis and secretory granule pathways in the
lung (Figures S7A and S7B). LincRNA-Cox2 is highly expressed
in the lung in a very cell type-specific manner (Figures S1B and
S1C). Using the Mouse Cell Atlas generated by Han et al.,
2018, we can show the differences in cell type expression
between Ptgs2 and lincRNA-Cox2 (Figure S1B). Overall,
lincRNA-Cox2 has a higher expression in specific immune-
related cells in the lung, whereas Ptgs2 has higher expression
in epithelial and endothelial cells, providing additional evidence
that lincRNA-Cox2 has distinct roles in trans independent of its
regulation of Ptgs2.
lincRNA-Cox2 Controls Immune Genes in trans
Independent of Ptgs2 following LPS Challenge In Vivo
The generation of the mutant intron-less lincRNA-Cox2 loss-
of-function model allowed us to assess the contribution of the
lincRNA transcript in vivo independent of the cis effect on
Ptgs2. We askedwhether the absence of the lincRNA-Cox2 tran-
script affects in vivo responses to LPS. We challenged the
lincRNA-Cox2 mutant mice in vivo by i.p. injection of E. coli
LPS. The temperature of the mice, a clinical parameter of septic
shock, decreased over time in both strains (Figure 7A). Serum
cytokines were then measured using multiplex assays. Inter-
feron-stimulated genes, including Ccl5 (Rantes) and Ip10, were
both found at elevated levels in the lincRNA-Cox2 mutant mice
following LPS challenge (Figures 7B and 7C), whereas proinflam-
matory gene expression, including Il5, Lif, and Il17, was reduced
(Figures 7D–7F). Tnfa expression levels were unchanged in con-
trol and mutant mice (Figure 7G). These in vivo data are consis-
tent with published in vitro data showing that lincRNA-Cox2 can
act to both promote and inhibit the expression of innate immune
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Figure 7. lincRNA-Cox2 Controls Innate Immune Cells in trans In Vivo
(A–G)WT andMutant mice were challenged with 20mg/kg LPS, and body temperature wasmeasured (A). Mice were sacrificed after 6 hr, cardiac punctures were
performed, serum was isolated, and multiplex cytokine analysis was performed for Ccl5 (B), Ip10 (C), Il5 (D), Lif (E), Il17 (F), and Tnfa (G). Each dot represents an
individual animal. Error bars represent standard deviation of biological triplicates. Student’s t tests were performed using GraphPad Prism. Asterisks indicate
statistically significant differences between mouse lines (*pR 0.05, **pR 0.01, ***pR 0.005).
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genes. Because all genes affected in the mutant mice were
located on different chromosomes to lincRNA-Cox2 (chromo-
some 1), these data confirm that lincRNA-Cox2 functions in trans
to control immune responses in vivo.
DISCUSSION
lincRNAs remain an understudied class of genes specifically in
the context of the immune system. Although there are a num-
ber of studies, both by our lab and others, showing that
lincRNA-Cox2 promotes and restrains different classes of
innate immune gene expression, none have shown the func-
tion of this gene in vivo (Carpenter et al., 2013; Covarrubias
et al., 2017; Hu et al., 2016; Tong et al., 2016; Xue et al.,
2018). Here we expand our knowledge of the role of
lincRNA-Cox2 by generating two murine models and multiple
macrophage cell lines, which strengthens our earlier findings
that lincRNA-Cox2 can inhibit expression of ISGs and enhance
pro-inflammatory gene expression. In addition, we now reveal
that lincRNA-Cox2 also functions through an eRNA mecha-
nism to control the expression of the neighboring gene Ptgs2
(Cox2) in vivo.
We initially characterized the lincRNA-Cox2 KO mouse,
generated by replacing the locus with LacZ, by tracking
LacZ expression in organs after LPS challenge. We observed
that lincRNA-Cox2 was highly expressed in the lung, and
further analysis of RNA-seq data confirmed this observation.
To determine how loss of lincRNA-Cox2 expression affects
gene expression at steady state, we performed RNA-seq on
lung samples comparing WT and KO. We were intrigued to
identify Ptgs2 among the most significantly altered transcripts
in the KO lung. Our previous work using shRNA-mediated
knockdown of lincRNA-Cox2 had not revealed any change in
the expression levels of Ptgs2 in BMDMs (Carpenter et al.,
2013), suggesting that this cis activity was carried out through
an enhancer within the DNA of this locus. We were unable to
rescue the expression of Ptgs2 by ectopic overexpression of
lincRNA-Cox2, further suggesting that it is either the DNA
responsible for the phenotype or that locus-specific expres-
sion of the transcript is required for this function. A caveat
with the reconstitution experiment is that we express
lincRNA-Cox2 off a plasmid using an EF1a promoter. Although
the reconstituted lincRNA-Cox2 localizes to the nucleus and
cytoplasm in a similar manner as the native transcript, it is
no longer induced by its native promoter or undergoing
splicing. Additional experiments, including ectopic expression
of lincRNA-Cox2 with the native promoter or the entire locus,
could help determine whether these features are critical for
the function of lincRNA-Cox2 in controlling Ptgs2 in cis. The
majority of the sequence for lincRNA-Cox2 lies within exon
2, and removing this exon using CRISPR resulted in a dramatic
decrease in Ptgs2. However, when we examined the locus for
enhancer elements, we did not identify any within exon 2 of the
gene. Instead, we observed evidence for DNA enhancer ele-
ments that lie only within the promoter of lincRNA-Cox2,
including H3K4 mono-methylation (H3K4me1) and p300
ChIP-seq. Interestingly, this enhancer region remained intact
in the lincRNA-Cox2 KO mouse, and the locus was transcrip-
tionally active, but Ptgs2 was downregulated. This indicates
that locus-specific transcription of lincRNA-Cox2 is required
to mediate the activity in cis, suggesting that lincRNA-Cox2
functions as a form of eRNA.
It has been reported that many lincRNAs act locally, explaining
why lincRNAs, like lincRNA-Cox2, display a similar expression
pattern as their neighboring protein-coding genes. A recent
study by Engreitz et al. (2016) showed that lncRNA and pro-
tein-coding genes can function locally and affect each other’s
expression levels. They show that 5 of 12 lincRNA loci they stud-
ied affected their neighboring gene in cis either through enhancer
activity from within the promoter through the act of transcription
or the act of splicing of the lincRNA (Engreitz et al., 2016).
eRNAs are produced from transcriptionally active enhancer
regions, which are epigenetically defined by high levels of
H3K4me1, low levels of H3K4 trimethyl (H3K4me3), and high
levels of histone 3 lysine 27 acetylation (H3K27Ac) (Creyghton
et al., 2010; Heintzman et al., 2007; Visel et al., 2009). lincRNAs
that function in cis to either enhance or suppress the expression
of neighboring protein-coding genes can be classified as
enhancer or repressor RNAs. Studies from IIott et al., 2014
identified over 40 canonical lincRNAs that act as eRNAs to
regulate protein-coding genes upon LPS stimulation in human
monocytes. Interestingly, although we found that knocking out
lincRNA-Cox2 greatly affected Ptgs2, deletion of Ptgs2 itself
did not affect basal or inducible levels of lincRNA-Cox2,
showing that the effects are not reciprocal between these two
loci. This result was further confirmed using CRISPRi, which
mediates heterochromatin formation and silencing of gene tran-
scription. Knocking down the transcription of Ptgs2 by over
90% had no effect on the regulation of lincRNA-Cox2. The
lincRNA-Cox2 locus has both high H3K4me1 and H3K4me3
marks, making it distinct from the typical definition of eRNAs.
It is possible that, as the field and function of lncRNAs con-
tinues to grow, that the categories that define their functions
will also expand.
To determine whether transcription of lincRNA-Cox2 is impor-
tant to regulate Ptgs2, we knocked down expression of the gene
usingCRISPRi. Our data show that we can knock down lincRNA-
Cox2 expression more than 95%, which equally affects Ptgs2
expression by more than 95%. In addition, using active Cas9,
we knocked out exon 2 of lincRNA-Cox2 (the majority of the
lincRNA-Cox2 sequence), this perturbation also affected Ptgs2
expression. Because we did not identify any possible enhancer
marks within exon 2, and all of the enhancer marks were within
the promoter, we conclude that lincRNA-Cox2 is functioning
through an eRNAmechanism to control Ptgs2. Although unlikely,
it is possible that there is an unidentified enhancermarkwithin the
DNA of exon 2. Future work aimed at inserting stop cassettes
within exon 2 could confirm that, indeed, transcription of the
gene is essential for Ptgs2 levels. The data we generated from
our ‘‘intron-less splicing mutant’’ mice strongly suggest that
this is the case. We used CRISPR/Cas9 to generate the mutant
mouse. In this mouse, the exons of the lincRNA-Cox2 transcript
aremaintained; however, the intron and splice sites are removed.
This mouse expressed basal levels of lincRNA-Cox2; however,
the transcript is no longer inducible following LPS stimulation. It
is possible that, because this transcript is no longer undergoing
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splicing, that it is highly unstable and, therefore, rapidly degraded
following LPS stimulation. In the future, northern blots should be
performed to confirm there are noadditional unexpected lincRNA
fragments in this model. Effectively, this mouse functions as a
transcript loss-of-function mouse model of lincRNA-Cox2. Our
studies with BMDMs and mice in vivo suggest that splicing is
not required for the observed effect on Ptgs2. Low basal expres-
sion of the spliced lincRNA-Cox2 transcript is sufficient to acti-
vate the Ptgs2 locus, further suggesting that, indeed, this gene
can function through an eRNA mechanism.
A final experiment was performed to assess whether lincRNA-
Cox2 is regulating Ptgs2 on the same chromosome. We crossed
our C57/Bl6 WT and KO mice with MOLF mice, which contain
millions of SNPs, allowing us to differentiate between the two al-
leles. Studying the Ptgs2 locus, we found that only expression
from the cis (C57/Bl6) allele was affected when lincRNA-Cox2
was knocked out. These data confirmed that indeed lincRNA-
Cox2 functions to regulate Ptgs2 on the same chromosome.
We predict that lincRNA-Cox2 is functioning as an eRNA and
the RNA is tethering the enhancer to the Ptgs2 locus and forming
a topologically associating domain. Further work including per-
forming 3C/Hi-C should confirm this.
The lincRNA-Cox2 mutant mice are a critical model enabling
us to study the trans activity for lincRNA-Cox2 independent of
its effects on Ptgs2. As mentioned previously, this mouse func-
tions as a transcript loss-of-function mouse model of lincRNA-
Cox2. The original lincRNA-Cox2 KOmouse not only attenuated
the expression of lincRNA-Cox2 but also repressed the expres-
sion of Ptgs2, whereas this model only affects lincRNA-Cox2
levels, enabling us to use these models to distinguish between
the cis and trans functions for this gene.
Distinct tissue-specific functions have been shown for several
lincRNAs. One such example is NEAT1, which is critical for syn-
apse formation in the brain (Sunwoo et al., 2017), whereas, in ad-
ipose tissue, NEAT1 is necessary for the differentiation of white
adipocytes (Cooper et al., 2014). lincRNA-Cox2 KO and mutant
mice were used to globally study the cis and trans role of
lincRNA-Cox2 in vivo by performing RNA-seq on lungs and
spleens from LPS-challenged WT, KO, and mutant mice. Not
surprisingly, we observed over 300 genes that were differentially
regulated when comparing KO with WT mice, whereas only half
that number were affected when comparing mutants with the
WT. We believe that this is due to the fact that the mutant mice
reveal only the functions of lincRNA-Cox2 in trans, whereas the
KO mice exhibit both cis effects on Ptgs2 and trans effects.
Interestingly, the mutant mice possessed differentially ex-
pressed genes in the lung and spleen, emphasizing a possible or-
gan-specific role for lincRNA-Cox2. Indeed,weobserve very high
levels of lincRNA-Cox2 in the lung, whereas the transcript is only
induced in the spleen following inflammatory stimulation. Further
workwill be needed to understandmechanistically how lincRNA-
Cox2 affects inflammatory responses in the lung and spleen.
From our LacZ staining within the lung, combined with data
from the mouse cell atlas, we observe cell type-specific expres-
sion patterns for lincRNA-Cox2. In the future, it will be informative
to isolate these specific cells for further mechanistic studies.
Finally, we wanted to determine whether lincRNA-Cox2 can
affect gene expression in the periphery following LPS challenge
in vivo. We observe an increase in Ccl5 and Ip10 (Cxcl10) levels
and a decrease in Il5, Il17, and Lif levels in the serum of mice
following endotoxic shock, suggesting that lincRNA-Cox2 can
function in trans to control various innate immune genes. These
data highlight two important features of this lincRNA’s function:
the in vivo immune-regulatory activity of lincRNA-Cox2 on im-
mune gene expression and the role of the lincRNA-Cox2 locus
in controlling Ptgs2 (Cox2) levels. Together, these studies further
our understanding of how lincRNAs can function both in cis
and in trans to control gene expression, findings that are only
evident through the use of multiple complimentary genetic
perturbations. The drastic influence of non-coding genes on
key immune signaling axes, such as the prostaglandin pathway
as shown here, has broad translational implications because it
indicates that protein-centered sequencing approaches are
likely insufficient to fully understand genetically mediated
autoimmune and auto-inflammatory conditions. Large-scale
functional validations of noncoding mutations, facilitated by
CRISPR/Cas9, will provide a promising approach to better un-
derstand the pathogenesis of inflammatory and non-inflamma-
tory diseases. CRISPR/Cas9 technology has revolutionized the
field of genome editing and will be a critical tool moving forward
to enable rapid generation of animal models to fully characterize
any lincRNA locus.
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gRNA_Cas9_Mutant_lincRNA-Cox2_dnstrm_g2 TACAGCATGTCTCCTGCAAA
gRNA_Cas9_Mutant_lincRNA-Cox2_upstrm_g1 CTGTCAGATGTATCTTATTT
gRNA_Cas9_Mutant_lincRNA-Cox2_upstrm_g2 GCTTGGCGTTGTGAAAAAGC
gRNA_Cas9_Ctl (non-targeting) GTCCATACGCATAATCACCG
gRNA_Cas9_lincRNA-Cox2_KO_dnstrm_g1 ATCATTAACCTGTTATCATA
gRNA_Cas9_lincRNA-Cox2_KO_dnstrm_g2 CTTCAATAGACATATCTTTA
gRNA_Cas9_lincRNA-Cox2_KO_upstrm_g1 TCTTTGATGCAAGGAACTAC
gRNA_Cas9_lincRNA-Cox2_KO_upstrm_g2 TTACACTGTTTATCGCTGGT
gRNA_Cas9_lincRNA-Cox2_KO_Exon2_Upstream_g1 CATTTATTATCTCCCTTTGC
gRNA_Cas9_lincRNA-Cox2_Exon2_Upstream_g2 TACAGCATGTCTCCTGCAAA
gRNA_Cas9_lincRNA-Cox2_Exon2_Downstream_g1 ATCATTAACCTGTTATCATATGG
gRNA_CRISPRi_NT (Nontargeting) CCTACACGACGAACGCAGGT
CRISPRi_lincRNA-Cox2_gRNA1 GTCCCGCGCATGATCTTGGA
CRISPRi_lincRNA-Cox2_gRNA2 TCTTGGAGGCAAACGCAGAG
CRISPRi_Ptgs2_gRNA1 AGTCAGGACTCTGCTCACGA
CRISPRi_Ptgs2_gRNA2 TCGTGAGCAGAGTCCTGACT
MOLF_Ptgs2lastexon_fwd gaaCCAcctTGTTGGACAGGAGAGAAGGAAATGGC
MOLF_Ptgs2lastexon_rev CCAGCTTAGCCGCCTTTTGATTAGTACTGTAGGG
Illumina_MOLF_Fwd-index1 aatgatacggcgaccaccgagatctacacgatcggaagagcacacgtctgaactccagtcacCTTGTA
gcacaaaaggaaactcaccct
(Continued on next page)
e2 Cell Reports 25, 1511–1524.e1–e6, November 6, 2018
CONTACT FOR RESOURCE AND SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead Contact, Susan
Carpenter (sucarpen@ucsc.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Maintenance of mice
UMass Medical School, UCSC and the Institutional Animal Care and Use Committee maintained mice under specific pathogen-free
conditions in the animal facilities of University of Massachusetts Medical School and University of California Santa Cruz (UCSC) in
accordance with the guidelines.
LincRNA-Cox2 KO mice
LincRNA-Cox2 deficient mice were generated as previously published (Sauvageau et al., 2013). Briefly, the entire lincRNA-Cox2 lo-
cus was deleted (deletion size 5.9 kB, targeting vector coordinates in mm9 coordinates: chr1:152006173-152012078) using Veloc-
iGene technology and replaced with a lacZ reporter cassette, enabling reporter gene expression under the endogenous lincRNA-
Cox2 promoter. Initially, the targeting constructs were electroporated into VGF1 hybrid mouse embryonic stem (ES) cells, derived
from a 129S6S v/Ev female to a C57BL/6male. Speed congenics were performed at Jackson laboratory to obtain a fully backcrossed
(99%) C57/BL6 lincRNA-Cox2 line.
Ptgs2 (Cox2) f/f VavCre mice
For the generation of conditional Ptgs2 deficient BMDMs, floxed Ptgs2mice which were generated on a C57/B6 and 129SV chimeric
background (Wang et al., 2009) were crossed to mice expressing VavCre, thereby generating mice lacking Ptgs2 expression
in all hematopoietic cells. Successful deletion of exons 6,7 and 8 of Ptgs2 was confirmed by genomic PCR, Western Blot and
RT-qPCR using the primers published previously (Anderson et al., 2015).
CRISPR/Cas9-mediated generation of LincRNA-Cox2 intron-less mice
The guide RNA sequences targeting upstream and downstream of the intron of lincRNA-Cox2 are tabulated below. Guides were
cloned using the same approach as described earlier. Once sgRNAs were confirmed by sequencing they were intro transcribed
by inserting a T7 ahead of the guide sequence and using the megashortscript T7 kit from Ambion. The sgRNAs are purified using
MEGAclear Transcription Clean-Up Kit (ThermoFisher) and eluted in elution buffer, followed by an additional ammonium acetate pre-
cipitation to concentrate the RNA. The concentrated sgRNA is re-suspended in nuclease-free water and prepared at a concentration
approximate to 2 ug/ul. To prepare Cas9 we obtained the vector from Addgene 42229.We used this as a template for a PCR reaction
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Illumina_MOLF_Fwd-index2 aatgatacggcgaccaccgagatctacacgatcggaagagcacacgtctgaactccagtcacGCCAAT
gcacaaaaggaaactcaccct
Illumina_MOLF_Fwd-index3 aatgatacggcgaccaccgagatctacacgatcggaagagcacacgtctgaactccagtcacAGTTCC
gcacaaaaggaaactcaccct
Illumina_MOLF_Fwd-index4 aatgatacggcgaccaccgagatctacacgatcggaagagcacacgtctgaactccagtcacTAGCTT
gcacaaaaggaaactcaccct
Illumina_MOLF_Rev CAAGCAGAAGACGGCATACGAGATCGACTCGGTGCCACTTTTTC
Recombinant DNA
pSICO empty vector zeocin This paper
pSICO lincRNA-Cox2 vector zeocin This paper
pSICO lentiviral vector Covarrubias et al., 2017
Software and Algorithms
GraphPad Prism V8 GraphPad
Office for Mac Microsoft
Illustrator CS6 Adobe
Bowtie Adobe http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
Samtools Li et al., 2009 http://samtools.sourceforge.net/
DeSeq2 Love et al., 2014
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to insert T7 using the following primers F:TAATACGACTCACTATAGGGAGAATGGACTATAAGGACCACGAC, R: GCGAGCTCTAG
GAATTCTTAC. The mRNA transcript was generated using mMESSAGEmMACHINE T7 ULTRA kit from Life Technologies according
to themanufactorers protocol. Cas9was used at a final concentration of 100ng/ul and the guides at 25ng/ul andwere injected into the
cytoplasm of fertilized oocytes at the injection facility at UCSF.
Cell culture and BMDM differentiation
Cells were cultured in D-MEM with 10% fetal bovine serum (FCS) supplemented with penicillin/streptomycin and ciprofloxacin.
Primary BMDM were generated by cultivating erythrocyte-depleted bone marrow cells in the presence of 20% L929 supernatant
and the cells were used for experiments 6-9 days after differentiation. J2Cre virus (Blasi et al., 1989) was used on day 3/4 after
isolation of bone marrow cells to establish transformed BMDM cell lines. BMDMs were cultivated in the presence of J2Cre virus
for 48h and L929 was then gradually tapered off over 6-10 weeks depending on the growth pattern of transformed cells.
METHOD DETAILS
LPS shock model
Age- and sexmatched wild-type andmutant mice (8-12 weeks of age) were injected i.p. with 20mg/kg LPS (E.coli). For gene expres-
sion analysis and cytokine analysis, mice were euthanized 6 h post injection. Blood was taken immediately post mortem by cardiac
puncture. Serum was isolated and sent to Eve technologies for cytokine analysis. Statistics were performed using GraphPad prism.
In vitro stimulation of BMDMs
Bonemarrow cells were stimulatedwith Toll-like receptor (Tlr) ligands for the indicated time points using the following concentrations:
Lipopolysaccharide (LPS) 100ng/ml (Tlr4), Pam3CSK4 100ng/ml (Tlr1/2), Pam2CSK4 100ng/ml (Tlr2/6), Poly(I:C) 25 mg/ml (Tlr3), R848
1mg/ml (Tlr7/8). For RNA and protein isolation, 1-2x106 cells were seeded in a 12-well format, for cytokinemeasurement 1-2x105 cells
were plated in 96-well plates. Normalization of cell number for ELISA experiments was performed by CellTiter Glo Analysis.
Transfection and stable lentiviral overexpression of lincRNA-Cox2
The sequence of lincRNA-Cox2 (synonym: Ptgs2os2) has been previously published (Carpenter et al., 2013; Guttman et al., 2009).
Stable lentiviral overexpression and trans-rescue was performed with a pMSCVneo retroviral vector containing themature sequence
of lincRNA-Cox2 (Carpenter et al., 2013). For generation of self-inactivating retroviral particles, HEK293T cells were transfected with
packaging vectors VSVg (1mg), Gag-Pol (1mg) and pMSCVneo-lincRNA-Cox2 (3mg). Genejuice was used as a transfection reagent
according to manufacturer’s instructions. Transfection media was removed 5h after transfection. Viral supernatants were
collected 48 and 72 hours after transfection, filtered and used for transduction of BMDMs. BMDMs were incubated with viral super-
natants for 48 hours, and neomycin (100mg/ml) was used for selection of transduced cells. For electroporation of primary BMDMs,
cells were harvested from the bone marrow of WT and lincRNA-Cox2 KO mice and differentiated using MCSF from L929 cells as
previously described. On day 4 of differentiation cells were transfected with 2ug of lincRNA-Cox2 (pSico-vector) or with a control
pSico-vector using the Lonza AD electroporation BMDM kit (VPA1009) as per the manufacturer’s description.
CRISPR/Cas9 mediated deletion of lincRNA-Cox2 in immortalized BMDMs
The Cas9 construct was constructed from a pSico lentiviral backbone with an EF1a promoter expressing T2A flanked genes:
blastocidin resistant (blast), Blue Fluorescent Protein (BFP), and humanized Streptococcus pyogenes Cas9. The single guide RNA
(sgRNA) construct was also constructed from a pSico lentiviral backbone driven by EF1a promoter expressing T2A flanked genes:
puro and cherry. sgRNAs were expressed from a mouse U6 promoter. Cloning of 20nt sgRNA spacer forward/reverse oligos were
annealed and cloned via the AarI site. Immortalized bone marrow derived BMDMs (iMacs) were lentivirally infected with the Cas9
construct and was selected using blasticidin (1ug/ml) for 7 days. Cells were then lentivirially infected with either nontargeting guide
or the guides targeting lincRNA-Cox2 and were selected using puromycin (2ug/ml) for 7 days. Control and lincRNA-Cox2 targeted
cells were cloned out. Knockout of lincRNA-Cox2 was confirmed by RT-qPCR.
CRISPRi mediated KO of lincRNA-Cox2 and Ptgs2 in immortalized BMDMs
Similar to the Cas9 construct, our dCas9-krab plasmid was constructed from a pSico lentiviral backbone with an EF1a promoter ex-
pressing T2A flanked genes: blastocidin resistant (blast), Blue Fluorescent Protein (BFP), and humanized Streptococcus pyogenes
dCas9. The single guide RNA (sgRNA) construct was the same as described in the previous section. Immortalized bone marrow
derived BMDMs (iMacs) were lentivirally infectedwith the dCas9-krab (described above) construct andwas selected using blasticidin
(1ug/ml) for > 2 weeks to obtain dCas9-krab expressing cells. Cells were then lentivirially infected with either non-targeting guide or
gene targeted guide RNAs and were selected using puromycin (2ug/ml) for 7-14 days. Knockdown of lincRNA-Cox2 or Ptgs2 was
confirmed by qRT-PCR.
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RNA isolation and cDNA synthesis and RT-qPCR
Total cellular RNA from BMDM cell lines or tissues was isolated using the Direct-zol RNAMiniPrep Kit (Zymo Research) according to
manufacturer’s instructions. For tissue, RNA was isolated with the TRIZOL method after tissue homogenization. RNA was quantified
and controlled for purity with a nanodrop spectrometer. (Thermo Fisher). For RT-qPCR, 500-1000 ng were reversely transcribed
(iScript Reverse Transcription Supermix, Biorad) followed by RT-PCR (iQ SYBRgreen Supermix, Biorad) using the cycling conditions
as follows: 50C for 2min, 95C for 2min followed by 40 cycles of 95C for 15 s, 60C for 30 s and 72C for 45 s. Themelting curvewas
graphically analyzed to control for nonspecific amplification reactions.
RNA-Sequencing
For generation of RNA-Sequencing libraries, RNA was isolated as described above and the RNA integrity was tested with a
BioAnalyzer (Agilent Technologies) or FragmentAnalyzer (Advanced Analytical). For RNA-Sequencing target RIN score of input
RNA (500-1000ng) usually had a minimum RIN score of 8. RNA-Sequencing libraries were prepared with TruSeq stranded
RNA sample preparation kits (Illumina), depletion of ribosomal RNA was performed by positive selection of polyA+ RNA.
Sequencing was performed on Illumina HighSeq or NextSeq machines. RNA-seq 50bp reads were aligned to the mouse genome
(assembly GRCm38/mm10) using TopHat. The Gencode M13 gtf was used as the input annotation. Differential gene
expression specific analyses were conducted with the DESeq R package. Specifically, DESeq was used to normalize gene
counts, calculate fold change in gene expression, estimate p values and adjusted p values for change in gene expression values,
and to perform a variance stabilized transformation on read counts to make them amenable to plotting. Data was submitted to
GEO GSE117379.
MiSeq
For theMOLF experiment, 5ul of cDNA fromMOLF-WT orMOLF-KO (2mice each) was used to template a PCR reaction using 1uMof
primers: Ptgs2lastexon_fwd: gaaCCAcctTGTTGGACAGGAGAGAAGGAAATGGC and Ptgs2lastexon_rev: CCAGCTTAGCCGCCT
TTTGATTAGTACTGTAGGG and using the following cycle parameters: 1x (98C for 30 s), 20x (98C for 15 s, 56C for 15 s, 72C for
30 s) and 1x (72C for 10 min) using phusion 2X master mix (ThermoFisher, F0531). PCR products (MOLF-WT, MOLF-WT, MOLF-
KO, MOLF-KO) were purified using Macherey-Nagel Gel-extraction columns, were digested with BstXI/Blp and were ligated into
pU6-sgRNA vector (https://benchling.com/s/CXQ8OiQn/edit) (gift from theWeissman Lab, UCSF) using standard T4 ligase. Ligation
was transformed, and coverage was determined to be > 200 colonies for each ligation. Using 1ul of the ligation reaction, we template
a second PCR reaction using 1uM of the custom illumina primers (Liu et al., 2017).
Using the following cycle parameters: 1x (98C for 30 s), 20x (98C for 15 s, 56C for 15 s, 72C for 30 s) and 1x (72C for 10 min).
PCR products were gel extracted on a 1% agarose gel and were purified using Macherey-Nagel Gel-extraction columns.
Amplicons were sequenced on the MiSeq using the custom sequencing. For each sample, counts were generated for MOLF
or C57/Bl6 Ptgs2 alleles respectably using sequences: and were normalized to total reads for analysis. Data was submitted to
GEO GSE117379.
Measurement of prostaglandins by mass spectrometry
Prostaglandin E2 production was measured by liquid chromatography/mass spectrometry as previously described 16. Briefly super-
natants were collected fromWild-Type or KO BMDMs following LPS stimulation for 6h. Systemic production of PGE2, determined by
quantifying the major urinary metabolites 7-hydroxy-5, 11-diketotetranorprostane-1, 16-dioic acid (PGEM). Results were normalized
with creatinine.
Western Blot Analysis
For western blotting, BMDMs were scraped, washed and lysed buffer containing 20mM Tris-HCl (pH 7.4), 1% NP-40 and
5mM EDTA supplemented with Protease inhibitor (Promega). Clarified samples were separated by SDS-PAGE and
transferred to PVDF membranes using the Trans-Blot Turbo Transfer System (BioRad). After blocking of the PVDF membrane
with PBS containing 5% (w/v) skim-milk powder and 0.1% Tween-20, the blots were probed with anti-COX2 (Cayman Item
#160106) or anti-Actin (Sigma) antibodies. Visualization was performed with enhanced chemiluminescence substrate (ECL
Pierce).
LacZ staining
For detection of reporter gene expression in lincRNA-Cox2 deficient mice, selected tissue was dissected and fixed in 4% parafor-
maldehyde (PBS) for 5 hours (4C). Fixed tissues were washed 3x with wash buffer (2mMMgCl2, 0,01%sodium deoxycholate, 0,02%
NP-40) and subsequently incubated in staining buffer (1mg/ml X-Gal, 5mM potassium ferricyanide, 5mM potassium ferrocyanide,
2mM MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40) in the dark overnight (room temperature). Staining solution was rinsed
off with PBS 3x and tissue were frozen in OCT on dry ice and sectioned in 10mm sections.
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QUANTIFICATION AND STATISTICAL ANALYSIS
For in vivo studies
All in vivo studies were carried out using nR 5. In every figure, each dot represents an individual animal. Student’s t tests were per-
formed using GraphPad Prism7. Asterisks indicate statistically significant differences between mouse lines (* = > 0.05, ** = > 0.01
and *** = > 0.005).
For in vitro studies
Data represents 3 combined biological replicates, representative of 3 individual experiments. Student’s t tests were performed using
GraphPad Prism7. Asterisks indicate statistically significant differences betweenmouse lines (* = > 0.05, ** = > 0.01 and *** = > 0.005).
DATA AVAILABILITY
All sequencing data generated from Mi-Seq and RNA-seq reported in this paper have been deposited to GEO under the ID code
GSE117379.
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